CAMBRIA-1: A Phase III Open-Label Randomised Study to Assess Efficacy & Safety of Extended Therapy with Camizestrant (AZD9833, Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in ER+/HER2- Early Breast Cancer & Intermediate or High Risk of Recurrence Who Have Completed Definitive Locoregional Therapy and at Least 2 Years Standard Adjuvant Endocrine-Based Therapy Without Disease Recurrence (enrollment paused 11-Apr-2025)

Objective

Clinical Trial Details

IRB Protocol Number

2023.031

Principal Investigator(s)

Jason Jones, MD

Clinical Trial Categories

• Breast Cancer

Contact

Breast Research Coordinators at 605-322-1432
or breastresearch@avera.org